Vimizim
Payments companies reported to CMS as associated with Vimizim. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vimizim, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vimizim
These are the largest totals companies reported as associated with Vimizim. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Paul Harmatz | Oakland, CA | Pediatric Gastroenterology | $12,276.89 |
| Barbara Burton | Chicago, IL | Clinical Genetics (M.D.) | $9,950.00 |
| Vernon Sutton | Houston, TX | Pediatrics | $3,648.00 |
| Cathleen Raggio | Uniondale, NY | Pediatric Orthopaedic Surgery | $2,275.00 |
| Klane White | Aurora, CO | Pediatric Orthopaedic Surgery | $1,950.00 |
| Emily Delosreyes | Columbus, OH | Neurology With Special Qualifications In Child Neurology | $114.55 |
| Nadia Merchant | Washington, DC | Pediatric Endocrinology | $80.43 |
| Roopa Kanakatti Shankar | Washington, DC | Pediatric Endocrinology | $80.43 |
| Andrew Dauber | Cincinnati, OH | Pediatric Endocrinology | $80.43 |
| David Rogers | Columbus, OH | Ophthalmology | $40.41 |
Prescribed Vimizim?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.